# High-dose Rifampicin for the Treatment of Tuberculous Meningitis: a Dose-finding Study

> **NCT02169882** · PHASE2,PHASE3 · COMPLETED · sponsor: **Universitas Padjadjaran** · enrollment: 60 (actual)

## Conditions studied

- Tuberculosis, Meningeal

## Interventions

- **DRUG:** Placebo
- **DRUG:** Rifampicin
- **DRUG:** Other TB drugs
- **DRUG:** Adjuvant dexamethasone

## Key facts

- **NCT ID:** NCT02169882
- **Lead sponsor:** Universitas Padjadjaran
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-01
- **Primary completion:** 2016-11-05
- **Final completion:** 2017-05-05
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2017-06-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02169882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02169882, "High-dose Rifampicin for the Treatment of Tuberculous Meningitis: a Dose-finding Study". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02169882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*